Kite’s Yescarta Receives EU Marketing Approval

 Kite’s Yescarta Receives EU Marketing Approval

Kite’s Yescarta Receives EU Marketing Approval

Shots:
  • Post FDA approval in 2017, Yescarta (axicabtagene ciloleucel) receives EU marketing approval for the treatment of Relapsed or Refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL)
  • The approval is based on ZUMA-1 trial with (N=101) results: 72%( 73/101) responded to therapy; 51%(52/101) achieved complete response; with one-year infusion- 60% patients were alive
  • Kite’s Yescarta is first CAR T (chimeric antigen receptor T cell) therapy, approved for use in 28 countries of the European Union, Norway, Iceland and Liechtenstein
Click here to read full press release/ article | Ref: Gilead | Image:  Business Wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post